Nutriband to Present at Emerging Growth Conference Amid Development of Abuse-Deterrent Fentanyl Patch

Nutriband Inc. (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Wednesday, October 8, 2025, at 3 p.m. ET. The presentation will feature a fireside Q&A session with questions from the live virtual audience, and registered investors can schedule one-on-one meetings with Melnik following the presentation. Interested attendees can register at no cost through the conference's official website.

The company's participation in this investor conference comes at a critical time as Nutriband develops its portfolio of transdermal pharmaceutical products. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating its proprietary AVERSA technology. This technology represents a significant advancement in pain management safety, as it can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

A video webcast of the presentation will be available on Channelchek, Noble's investor portal, and will be archived for 90 days on both Channelchek.com and Nutriband's corporate website at www.nutriband.com. The archived availability ensures that investors and stakeholders who cannot attend the live event will have extended access to the company's strategic updates and financial outlook.

The timing of this presentation is particularly relevant given the ongoing opioid crisis and the urgent need for safer pain management alternatives. Nutriband's AVERSA technology addresses a critical gap in pharmaceutical safety by providing an additional layer of protection against opioid abuse. With fentanyl being one of the most potent and frequently abused opioids, an abuse-deterrent formulation could have substantial implications for public health and drug safety regulations.

For investors and industry observers, the conference presentation offers insight into Nutriband's progress in developing technology that could potentially transform pain management practices. The ability to prevent abuse of transdermal medications represents not only a significant medical advancement but also a substantial market opportunity in the pharmaceutical industry. As regulatory agencies increasingly emphasize the importance of abuse-deterrent formulations, companies like Nutriband that pioneer such technologies may be well-positioned for growth and partnership opportunities.

The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB, providing ongoing access to corporate developments and regulatory milestones. The combination of investor outreach through conferences like Noble Capital Markets' event and transparent communication through dedicated news channels demonstrates Nutriband's commitment to keeping stakeholders informed about its progress in developing potentially life-saving pharmaceutical technologies.